文献速递主动脉疾病

Zenith TX2夹层腔内移植物治疗Stanford B型主动脉夹层的早期结果

Early outcomes associated with use of the Zenith TX2 Dissection Endovascular Graft for the treatment of Stanford type B aortic dissection.
PubMed 文献 · J Vasc Surg · 2021-02-15

这项回顾性多中心病例队列研究汇总了2011至2018年10家欧洲机构使用Zenith TX2夹层腔内移植物(ZDEG)和Zenith夹层裸支架(ZDES)治疗Stanford B型主动脉夹层的120例患者数据。主要终点为30天和90天死亡率,结果显示30天内死亡7例(5.8%),30至90天死亡2例(1.7%),术后逆性A型夹层仅1例,总体并发症发生率较低。

要点

  • 30天死亡率为5.8%,90天累积死亡率为7.5%。
  • 逆性A型夹层发生率低于1%,仅见于破裂病例。
  • 联合使用ZDES的患者无截瘫、无永久透析、无需内脏动脉支架。

核心结论

  • ZDEG联合ZDES治疗B型主动脉夹层显示较低的逆性A型夹层发生率和良好的发病率与死亡率。
  • 联合使用ZDES的队列中截瘫、透析和内脏动脉支架置入率较低,值得进一步评估。

研究设计与样本

  • 回顾性多中心病例队列研究,汇总10家欧洲机构2011至2018年数据。
  • 共纳入120例接受ZDEG和ZDES治疗的Stanford B型主动脉夹层患者,其中男性87例,平均年龄62.7±12.2岁。

主要发现

  • 急性期76例(63.3%),亚急性期16例(13.3%),慢性期28例(23.3%)。
  • 30天内死亡7例(5.8%),30至90天死亡2例(1.7%)。
  • 术后逆性A型夹层1例,发生于破裂病例;卒中3例(2.5%),截瘫5例(4.2%)。
  • 围术期Ia型内漏8例(6.7%)。
  • 33例(27.5%)联合放置ZDES的患者中,无截瘫、无永久透析、无需肠系膜上动脉或腹腔干支架置入,且该组ZDEG长度和远端oversizing较小。

临床怎么用

  • 对于Stanford B型主动脉夹层,可考虑使用ZDEG联合ZDES进行腔内治疗,尤其关注联合ZDES可能降低截瘫和内脏动脉并发症。
  • 术后需监测逆性A型夹层、内漏、卒中和截瘫等并发症。

局限性

  • 回顾性研究设计,可能存在选择偏倚。
  • 样本量有限,联合ZDES的获益需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate short term outcomes related to the use of the Zenith TX2 Dissection Endovascular Graft (ZDEG) and the Zenith Dissection Bare stent (ZDES) for the treatment of Stanford type B aortic dissections. METHODS: This retrospective multicenter case cohort study collated data from 10 European institutions for patients with both complicated and uncomplicated type B aortic dissection treated with ZDEG and ZDES between 2011 and 2018. The primary end point was mortality at 30 and 90 days. Secondary end points included complications related to TEVAR, such as, type Ia endoleak, stroke, paraparesis, paraplegia, and retrograde type A dissection (RTAD). Statistical analysis was carried out using the t test, or one-way analysis of variance and the χ2 or Fisher exact tests. RESULTS: We treated 120 patients (87 male; mean age, 62.7 ± 12.2years) either in the acute 76 (63.3%), subacute 16 (13.3%), or chronic 28 (23.3%) phase. Seven patients (5.8%) died within 30 days after the index procedure and two (1.7%) between 30 and 90 days. There was one instance of postoperative RTAD in a patient treated for rupture. Stroke and paraplegia occurred in three (2.5%) and five (4.2%), patients, respectively. Eight patients (6.7%) had a type Ia endoleak in the perioperative period. There were no instances of paraplegia, no permanent dialysis, and no requirement for adjunctive superior mesenteric or celiac artery stenting in the 33 patients (27.5%) who were treated by concurrent placement of ZDES distal to the ZDEG. The length and distal oversizing of ZDEG components used was less in this group. CONCLUSIONS: The present series demonstrates a low (<1%) RTAD rate and favorable morbidity and mortality. The lower rate of paraplegia, dialysis, and visceral artery stenting in the cohort that had adjunctive use of ZDES is compelling and merits further assessment.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Patel JJ, Kasprzak P, Pfister K, et al. Early outcomes associated with use of the Zenith TX2 Dissection Endovascular Graft for the treatment of Stanford type B aortic dissection. J Vasc Surg. 2021. PMID: 33600932. doi:10.1016/j.jvs.2021.01.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。